Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma

Launched by VINODH KAKKASSERY, MD · Apr 21, 2023

Keywords

ClinConnect Summary

This clinical trial is focused on understanding a type of eye cancer called Vitreoretinal Lymphoma (VRL). Researchers want to learn more about the changes in proteins and genes in different fluids related to the eye, like the aqueous humour and vitreous humour, as well as blood samples. By studying these changes, the goal is to improve the way doctors diagnose and treat this disease. The trial aims to include at least 220 patients and will compare new testing methods with standard procedures to see which is more effective at identifying VRL.

To participate in this study, individuals must be over 18 years old and have a clinical suspicion of VRL that requires a specific eye procedure called vitrectomy. Participants will need to give their written consent to take part. Those who have recently received certain treatments for lymphoma or have specific eye conditions might not be eligible. During the study, participants will be monitored for two years to track their treatment response and any potential recurrence of the disease. This trial is not yet recruiting participants, but it represents an important step toward enhancing the understanding and management of Vitreoretinal Lymphoma.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical suspicion of the presence of VRL with indication for diagnostic vitrectomy. Clinical suspicion is based on the assessment of the treating physicians in the clinics participating in this study.
• • Age over 18 years.
• • Written informed consent to participate in the study.
• Exclusion Criteria:
• • Systemic chemotherapy for lymphoma within 3 months prior to vitrectomy.
• • Cortisone use within 2 weeks before vitrectomy, macular oedema, posterior synechiae, rubeosis iridis